Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03621670 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,196
- Enrollment target
NCT03621670 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,196 participants.
The verdict
NCT03621670, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,196 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccinesv(RIV).
Interventions
- BIOLOGICAL Rotarix
- BIOLOGICAL Pediarix
- BIOLOGICAL Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)
- BIOLOGICAL Prevnar13
- BIOLOGICAL Hiberix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,196 participants |
| Start Date | 2018-07-27 |
| Est. Completion | 2024-12-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03621670
The ClinicalTrials.gov registry entry for NCT03621670 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rotarix is the first listed.
NCT03621670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03621670 about?
NCT03621670 is a clinical study titled "Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants". The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant ...
What is the current status of trial NCT03621670?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,196 participants. The study started on 2018-07-27. Estimated completion is 2024-12-27.
What interventions are being tested in trial NCT03621670?
The interventions under investigation include: Rotarix (BIOLOGICAL), Pediarix (BIOLOGICAL), Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ) (BIOLOGICAL), Prevnar13 (BIOLOGICAL), Hiberix (BIOLOGICAL).
Who is sponsoring clinical trial NCT03621670?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.